HOME >> BIOLOGY >> NEWS
Experimental drug shown to block mutant protein causing blood disease

BOSTON--Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

The researchers also tested the drug, PKC412, in a patient with the hard-to-treat disease, called Myeloproliferative Disease (MPD), and saw her symptoms improve.

PKC412, like the spotlight drug Gleevec, is a highly specific "targeted" drug that disables a switch in cancer cells that has become jammed in the "on" position because of a genetic mutation. The glitch allows a continuous stream of signals to prod blood cells into an uncontrolled frenzy of division and growth. The overproduction of white blood cells in MPD damages organs and generally turns into an acute leukemia that can be fatal.

The report appears in this week's Online Early Edition of the Proceedings of the National Academy of Sciences. Jing Chen, PhD, of Brigham and Women's, and Daniel J. DeAngelo, MD, PhD, of Dana-Farber, are the paper's co-first authors. D. Gary Gilliland, MD, PhD, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital, and Richard M. Stone, MD, of Dana-Farber are the senior authors. Other authors are from Dana-Farber, Brigham and Women's, Harvard Medical School, Emory University, and Novartis Pharma AG.

"The study shows the potential utility of drugs that block mutant tyrosine kinases, and that these drugs are opening more doors to treating cancers," explains Stone.

Tyrosine kinases are molecules that act as biological switches inside cells, regulating processes including cell division and growth. Abnormal kinases have been discovered to be major culprits in many forms of cancer. Because inhibitor drugs strike the abnormal kinases in cancer cells without harming normal tissue, they are associated with fewer side effects than standard cancer drugs.

In the study, mice with MP
'"/>

Contact: Bill Schaller or Richard Saltus
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
21-Sep-2004


Page: 1 2

Related biology news :

1. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
2. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
3. Experimental Biology 2004 - Translating the Genome
4. Experimental Biology 2004 meets in Washington, D.C. April 17-21
5. Experimental hantavirus vaccine elicits strong antibody response in primates
6. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2017)... 2017  GCE Solutions, a global clinical research organization (CRO), announces ... solution on October 4, 2017. Shadow is designed to assist medical ... policy 0070 of the European Medicines Agency (EMA) in meeting the ... ... ...
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ... board any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to ... Delta,s biometric ... Sky Club is now integrated into the boarding process to allow ...
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... The award-winning ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... is faced with the challenge of how to continue to feed a growing nation. ...
Breaking Biology Technology:
Cached News: